A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Identifieur interne : 000D63 ( PubMed/Checkpoint ); précédent : 000D62; suivant : 000D64A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Auteurs : Nicolas Sabarth [Autriche] ; Helga Savidis-Dacho ; Michael G. Schwendinger ; Peter Brühl ; Daniel Portsmouth ; Brian A. Crowe ; Otfried Kistner ; P Noel Barrett ; Thomas R. Kreil ; M Keith HowardSource :
- Vaccine [ 1873-2518 ] ; 2012.
Descripteurs français
- KwdFr :
- Animaux, Anticorps hétérophiles, Anticorps neutralisants, Calendrier vaccinal, Cellules Vero (virologie), Femelle, Immunité cellulaire (immunologie), Immunité humorale, Rappel de vaccin, Relation dose-réponse (immunologie), Réactions croisées (immunologie), Souris, Sous-type H5N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (pathogénicité), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Immunité cellulaire, Réactions croisées, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- pathogénicité : Sous-type H5N1 du virus de la grippe A.
- virologie : Cellules Vero.
- Animaux, Anticorps hétérophiles, Anticorps neutralisants, Calendrier vaccinal, Femelle, Immunité humorale, Rappel de vaccin, Relation dose-réponse (immunologie), Souris.
English descriptors
- KwdEn :
- Animals, Antibodies, Heterophile, Antibodies, Neutralizing, Chlorocebus aethiops, Cross Reactions (immunology), Dose-Response Relationship, Immunologic, Female, Immunity, Cellular (immunology), Immunity, Humoral, Immunization Schedule, Immunization, Secondary, Influenza A Virus, H5N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (pathogenicity), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Mice, Vero Cells (virology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- chemical : Antibodies, Heterophile, Antibodies, Neutralizing.
- immunology : Cross Reactions, Immunity, Cellular, Influenza A Virus, H5N1 Subtype.
- pathogenicity : Influenza A Virus, H5N1 Subtype.
- virology : Vero Cells.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Immunologic, Female, Immunity, Humoral, Immunization Schedule, Immunization, Secondary, Mice.
Abstract
Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.
DOI: 10.1016/j.vaccine.2012.06.043
PubMed: 22749797
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22749797Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</title>
<author><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau</wicri:regionArea>
<wicri:noRegion>A-2304 Orth/Donau</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name>
</author>
<author><name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name>
</author>
<author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name>
</author>
<author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name>
</author>
<author><name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name>
</author>
<author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name>
</author>
<author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
</author>
<author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name>
</author>
<author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22749797</idno>
<idno type="pmid">22749797</idno>
<idno type="doi">10.1016/j.vaccine.2012.06.043</idno>
<idno type="wicri:Area/PubMed/Corpus">000C64</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C64</idno>
<idno type="wicri:Area/PubMed/Curation">000C64</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C64</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D63</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D63</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</title>
<author><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau</wicri:regionArea>
<wicri:noRegion>A-2304 Orth/Donau</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name>
</author>
<author><name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name>
</author>
<author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name>
</author>
<author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name>
</author>
<author><name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name>
</author>
<author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name>
</author>
<author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
</author>
<author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name>
</author>
<author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Heterophile</term>
<term>Antibodies, Neutralizing</term>
<term>Chlorocebus aethiops</term>
<term>Cross Reactions (immunology)</term>
<term>Dose-Response Relationship, Immunologic</term>
<term>Female</term>
<term>Immunity, Cellular (immunology)</term>
<term>Immunity, Humoral</term>
<term>Immunization Schedule</term>
<term>Immunization, Secondary</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (pathogenicity)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Mice</term>
<term>Vero Cells (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps hétérophiles</term>
<term>Anticorps neutralisants</term>
<term>Calendrier vaccinal</term>
<term>Cellules Vero (virologie)</term>
<term>Femelle</term>
<term>Immunité cellulaire (immunologie)</term>
<term>Immunité humorale</term>
<term>Rappel de vaccin</term>
<term>Relation dose-réponse (immunologie)</term>
<term>Réactions croisées (immunologie)</term>
<term>Souris</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (pathogénicité)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Heterophile</term>
<term>Antibodies, Neutralizing</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Immunité cellulaire</term>
<term>Réactions croisées</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cross Reactions</term>
<term>Immunity, Cellular</term>
<term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules Vero</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Dose-Response Relationship, Immunologic</term>
<term>Female</term>
<term>Immunity, Humoral</term>
<term>Immunization Schedule</term>
<term>Immunization, Secondary</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Anticorps hétérophiles</term>
<term>Anticorps neutralisants</term>
<term>Calendrier vaccinal</term>
<term>Femelle</term>
<term>Immunité humorale</term>
<term>Rappel de vaccin</term>
<term>Relation dose-réponse (immunologie)</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22749797</PMID>
<DateCompleted><Year>2013</Year>
<Month>04</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>37</Issue>
<PubDate><Year>2012</Year>
<Month>Aug</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</ArticleTitle>
<Pagination><MedlinePgn>5533-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2012.06.043</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Mice received one or two priming immunizations with a Vero cell culture-derived, whole-virus clade 1 H5N1 vaccine formulated to contain either 750 ng or 30 ng hemagglutinin. Six months after the first priming immunization, mice received either a booster immunization with the same clade 1 vaccine or a heterologous clade 2.1 vaccine, or buffer. Humoral and cellular immune responses were evaluated before and at regular intervals after immunizations. Three weeks after booster immunization, mice were challenged with a lethal dose of wild-type H5N1 virus from clades 1, 2.1 or 2.2 and survival was monitored for 14 days.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">One or two priming immunizations with the 750 ng or 30 ng HA formulations, respectively, induced H5N1-neutralizing antibody titers which were maintained for ≥ 6 months and provided long-term cross-clade protection against wild-type virus challenge. Both humoral and cellular immune responses were substantially increased by a booster immunization after 6 months. The broadest protective immunity was provided by an immunization regimen consisting of one or two priming immunizations with a clade 1 vaccine and a boosting immunization with a clade 2.1 vaccine.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data support the concept that pre-pandemic vaccination can provide robust and long-lasting H5N1 immunity which could be effectively boosted by immunization either with another pre-pandemic vaccine or with the pandemic strain vaccine.</AbstractText>
<CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabarth</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Savidis-Dacho</LastName>
<ForeName>Helga</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schwendinger</LastName>
<ForeName>Michael G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brühl</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Portsmouth</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Crowe</LastName>
<ForeName>Brian A</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kistner</LastName>
<ForeName>Otfried</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barrett</LastName>
<ForeName>P Noel</ForeName>
<Initials>PN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kreil</LastName>
<ForeName>Thomas R</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Howard</LastName>
<ForeName>M Keith</ForeName>
<Initials>MK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>06</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000910">Antibodies, Heterophile</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000910" MajorTopicYN="N">Antibodies, Heterophile</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2012</Year>
<Month>06</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2012</Year>
<Month>06</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22749797</ArticleId>
<ArticleId IdType="pii">S0264-410X(12)00909-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2012.06.043</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Autriche</li>
</country>
</list>
<tree><noCountry><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
<name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name>
<name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name>
<name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name>
<name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name>
<name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name>
<name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name>
<name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name>
<name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name>
</noCountry>
<country name="Autriche"><noRegion><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:22749797 |texte= A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22749797" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |